低分子肝素结合拉贝洛尔对妊娠期高血压疾病患者血压水平、凝血指标及妊娠结局的影响  

The effect of low molecular weight heparin combined with labetalol on blood pressure levels,coagulation indicators and pregnancy outcomes in patients with hypertensive disorders in pregnancy

作　　者：张鹂 陈桢 林颖 ZHANG Li;CHEN Zhen;LIN Ying(Obstetrics Department,Mindong Hospital of Ningde City,Fu'an 355000,China)

机构地区：[1]宁德市闽东医院产科,355000

出　　处：《中国现代药物应用》2025年第7期106-109,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨低分子肝素结合拉贝洛尔在妊娠期高血压疾病(HDP)患者中的治疗效果。方法102例HDP患者,按随机数字表法分为对照组及观察组,各51例。对照组予以拉贝洛尔基于对照组,观察组用低分子肝素。比较两组临床疗效,治疗前后的血压[收缩压(SBP)、舒张压(DBP)]、凝血指标[纤维蛋白原(FIB)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)]及血清学指标[血清同型半胱氨酸(Hcy)、C反应蛋白(CRP)、内皮素-1(ET-1)、一氧化氮(NO)]水平,妊娠结局,不良反应发生率。结果观察组总有效率95.08%高于对照组的82.35%(P<0.05)。治疗后,观察组SBP(127.15±5.62)mm Hg(1 mm Hg=0.133 kPa)、DBP(75.56±6.32)mm Hg低于对照组的(134.20±6.41)、(86.74±7.63)mm Hg(P<0.05)。治疗后,观察组FIB(3.02±0.42)g/L低于对照组的(3.51±0.65)g/L,APTT(31.32±2.15)s、PT(12.95±0.84)s、TT(15.14±1.05)s长于对照组的(27.38±2.54)、(12.14±0.70)、(13.09±1.07)s(P<0.05)。治疗后,观察组Hcy(10.32±1.43)μmol/L、CRP(6.25±1.15)mg/L、ET-1(42.46±4.32)ng/L低于对照组的(13.24±2.06)μmol/L、(8.16±1.25)mg/L、(47.64±4.10)ng/L,NO(88.06±6.14)μmol/L高于对照组的(79.30±5.77)μmol/L(P<0.05)。观察组不良妊娠结局发生率3.92%低于对照组的15.69%(P<0.05)。两组治疗期间均未发生不良反应。结论低分子肝素结合拉贝洛尔可以改善HDP患者血压及凝血指标,促进血清学指标复常,减少不良妊娠结局的发生,安全性高。Objective To explore the effect of low molecular weight heparin combined with labetalol in patients with hypertensive disorders in pregnancy(HDP).Methods 102 cases of HDP patients were divided into control group and observation group according to random numerical table,with 51 cases in each group.The patients of control group took labetalol,and on this basis,the patients of observation group took low molecular weight heparin.Comparisons were made on the clinical efficacy,blood pressure[systolic blood pressure(SBP),diastolic blood pressure(DBP)],coagulation indicators[fibrinogen(FIB),activated partial thromboplastin time(APTT),prothrombin time(PT),thrombin time(TT)],serum indicators[serum homocysteine(Hcy),C-reactive protein(CRP),endothelin-1(ET-1),nitric oxide(NO)]levels,pregnancy outcomes,and incidence of adverse reactions in both groups.Results The observation group obtained higher total effective rate than the control group(95.08%VS 82.35%)(P<0.05).The observation group had SBP of(127.15±5.62)mmHg(1 mmHg=0.133 kPa)and DBP of(75.56±6.32)mm Hg after treatment,which were lower than(134.20±6.41)and(86.74±7.63)mm Hg in the control group(P<0.05).After treatment,the observation group had a lower FIB of(3.02±0.42)g/L than(3.51±0.65)g/L in the control group;the observation group had APTT of(31.32±2.15)s,PT of(12.95±0.84)s and TT of(15.14±1.05)s,which were longer than(27.38±2.54),(12.14±0.70)and(13.09±1.07)s in the control group(P<0.05).After treatment,the observation group had Hcy of(10.32±1.43)μmol/L,CRP of(6.25±1.15)mg/L,and ET-1 of(42.46±4.32)ng/L,which were lower than(13.24±2.06)μmol/L,(8.16±1.25)mg/L,and(47.64±4.10)ng/L in the control group;the observation group had a higher NO of(88.06±6.14)μmol/L than(79.30±5.77)μmol/L in the control group(P<0.05).The observation group had lower incidence of adverse pregnancy outcome compared with the observation group(3.92%VS 15.69%)(P<0.05).The two groups of patients during treatment showed no significant adverse reactions.Conclusion Low molecular weigh

关 键 词：妊娠期高血压疾病 低分子肝素 拉贝洛尔 血压水平 凝血指标 妊娠结局 

分 类 号：R714.24[医药卫生—妇产科学]